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Abstract. Novel 1,4,5,8-naphthalentetracarboxylic diimide (NDI) derivatives were 
synthesized and evaluated for their antiproliferative activity on a wide number of 
tumor cell lines. The prototypes of the present series were derivatives 1 and 2 
characterized by interesting biological profiles as anticancer agents. The present 
investigation expands on the study of structure-activity relationships of prototypes 1 
and 2, namely, the effect of the substituents on the phenyl ring. Derivatives 3-22, 
characterized by a different substituent on the aromatic rings and/or a different chain 
length varying from two to three carbon units, were synthesized and evaluated for 
their cytostatic and cytotoxic activities. The most interesting compound was 20, 
characterized by a linker of three methylene units and a 2,3,4-trimethoxy substituent 
on the two aromatic rings. It displayed antiproliferative activity in the submicromolar 
range, especially against colon and prostate cancer cell lines, the ability to inhibit Taq 
polymerase and telomerase, to trigger caspase activation by a possible oxidative 
mechanism, to downregulate ERK 2 protein and to inhibit ERKs phosphorylation, 
without acting directly on microtubules and tubuline. Its theoretical recognition 
against duplex and quadruplex DNA structures has been compared to experimental 
thermodynamic measurements leading to putative binding models. Thanks to this 
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interesting biological profile 20 can be considered a multitarget anticancer agent and a 
promising lead compound for this class of derivatives. 
Introduction 
Naphtalene diimide (NDI) scaffold is present in a wide number of potential anticancer 
agents which interact with DNA preferentially as intercalators1-5. Additionally, some 
derivatives characterized by this core have been optimized to exhibit bis-threading 
intercalating ability6, to enhance the stabilization of DNA triplexes7, to stabilize8 or 
alkylate9,10 G-quadruplex DNA structure.  
One of the main prototype of NDI derivatives is represented by N-BDMPrNDI 
(Figure 1) which showed the ability to intercalate into steps containing at least one 
G:C base pair.11 Recently, we published a paper in which we reported a new series of 
NDI derivatives as antiproliferative agents.12 These compounds were characterized by 
NDI scaffold properly functionalized with two basic side chains which, in principle, 
should enhance both their solubility in aqueous media and interactions with  
 
 
Figure 1. Chemical structures of N-BDMPrNDI, 1 and 2. 
 
the DNA phosphate groups.13 This study was focussed on defining the influence of 
the length of the two basic side chains on antiproliferative activity by exploring 
linkers comprising from two to ten methylene units. A 2-methoxybenzyl substituent 
was introduced at the side chain terminal nitrogens because we reported its ability to 
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improve the basicity when inserted on terminal nitrogen atoms of polymethylene 
amines.14 We identified two lead compounds 1 and 2 (Figure 1) which showed an 
interesting antiproliferative activity in the micromolar range on SKBR-3, CEM and 
HL60 cell lines. Furthermore, they efficiently interacted with DNA, they triggered 
caspase activation, caused p53 protein accumulation, down-regulated AKT survival, 
and finally, caused a decrease of ERK1/2 and inhibited ERKs phosphorylation. All 
these biological properties might indicate these derivatives as multitarget ligands15. 
Since, cancer is a complex disease comprising numerous altered biological networks, 
this new class of compounds might represent a more comprehensive treatment of 
pathology.16  
In the present work we extended the study of structure-activity relationships of 
prototypes 1 and 2, including the effect of different substituents on the phenyl rings. 
In particular, we introduced 2-methoxybenzyl groups in different positions of the two 
aromatic rings as well as other chemical groups characterized by different aromatic 
effects to verify a their possible influence on the biological activities. Since the two 
prototypes differ in the length of the two basic side chains, the new synthesized 
compounds were divided in two series, in particular the 1-related series is constituted 
by the odd final derivatives 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21; the 2-related series 
by the even final compounds 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22. To note that 
fluorine derivatives 11 and 12 were also investigated for the peculiar effects of this 
substituent in many different derivatives.17  
Finally, the trimethoxybenzyl moiety, a common pharmacophore characterizing 
different well-known anticancer compounds such as Combrastatin A4, Colchicine and 
Podophyllotoxin all acting on tubulin skeleton, was inserted on the 1 and 2 scaffolds, 
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to give 19-22, with the aim to include some other new targets in their anticancer 
activity.  
All derivatives were screened by cytotoxic assays, and the more interesting were also 
evaluated by specific biological assays in order to elucidate their molecular 
mechanism. In particular, DNA interaction, apoptosis activation, specific enzymes 
inhibition investigations and molecular modelling studies were performed. 
 
Results and discussion 
Chemistry. Compounds 3-22 were synthesized following the procedure reported in 
Scheme 1 and were characterized by IR, 1H NMR, mass spectra, and elemental 
analysis. The appropriate aldehydes were treated with 1,2-diaminoethane or 1,3-
diaminopropane to afford the corresponding Schiff bases which were reduced with 
sodium borohydride to give compounds 23-42. Condensation of such derivatives with 
naphthalenetetracarboxylic dianhydride led to the corresponding diamines-diimides 3-
22. Di-p-toluensulfonates salts of all the compounds were prepared to obtain 
























R = 3-OCH3, 4-OCH3, H
      2-Cl, 2-F, 2-NO2, 
      2-CF3, 2-CH3, 
      2,3,4-OCH3, 3,4,5-OCH3
 23: n = 2, R = 3-OCH3              24: n = 3, R = 3-OCH3
 25: n = 2, R = 4-OCH3              26: n = 3, R = 4-OCH3
 27: n = 2, R = H                        28: n = 3, R = H
 29: n = 2, R = 2-Cl                    30: n = 3, R = 2-Cl
 31: n = 2, R = 2-F                     32: n = 3, R = 2-F,
 33: n = 2, R = 2-NO2                34: n = 3, R = 2-NO2
 35: n = 2, R = 2-CF3                 36: n = 3, R = 2-CF3
 37: n = 2, R = 2-CH3                 38: n = 2, R = 2-CH3
 39: n =2, R = 2,3,4-OCH3         40: n = 3, R = 2,3,4-OCH3
 41: n = 2, R = 3,4,5-OCH3        42: n = 3, R = 3,4,5-OCH3
 3: n = 2, R = 3-OCH3              4: n = 3, R = 3-OCH3
 5: n = 2, R = 4-OCH3              6: n = 3, R = 4-OCH3
 7: n = 2, R = H                        8: n = 3, R = H
 9: n = 2, R = 2-Cl                    10: n = 3, R = 2-Cl
 11: n = 2, R = 2-F                   12: n = 3, R = 2-F,
 13: n = 2, R = 2-NO2              14: n = 3, R = 2-NO2
 15: n = 2, R = 2-CF3              16: n = 3, R = 2-CF3
 17: n = 2, R = 2-CH3              18: n = 2, R = 2-CH3
 19: n =2, R = 2,3,4-OCH3       20: n = 3, R = 2,3,4-OCH3
 21: n = 2, R = 3,4,5-OCH3      22: n = 3, R = 3,4,5-OCH3  
a(i) (a) toluene, reflux, 3 h; (b) NaBH4, EtOH, room temp., 3 h, 24-36%; (ii) 1,4,5,8-Naphthalene-




As preliminary screening all new compounds were submitted to the Developmental 
Therapeutics Program (DTP)a at National Cancer Institute (NCI) for evaluation of 
their anticancer activity against human cell lines. The most active compounds were 
been object of further investigations to better elucidate their molecular mechanism. 
Growth-Inhibiting Activity. Although all substituted compounds of the two series 
were synthesized, only 8, 10, 12, 20 and 22 of the 2-series together with 3, 5, 19 and 
21 of the 1-series, in which the 2-methoxy group was moved at positions 3 and 4, 
respectively, were selected by National Cancer Institute (NCI, Bethesda), for 
evaluation in the full panel of about 60 human cancer cell lines. (Table 1). Finally, to 
complete the cytotoxic investigation of the 2-series, the effects of compounds 14, 16 
and 18 on growth inhibition of a more limited panel of tumor cell lines including: 
HTLA-230, OVCAR-3, MZ2-Mel 3.0 and SW620 were investigated (Table 2). 
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Compounds 6, 9, 11, 13, 15, 17 were evaluated only to a preliminary test at 10-5 M 
concentration for 48 h incubation (data not shown). Indeed, only compounds that 
satisfied predetermined threshold inhibition criteria in a minimum number of cell 
lines, based on the analysis of historical Developmental Therapeutics Program (DTP) 
screening data, progressed to the full five-concentration assay. Following these 
criteria, derivatives 1-3, 5, 7, 8, 10, 12, 19-22 were selected for evaluation in the full 
panel of about 60 human cancer cell lines derived from nine human cancer cell types, 
that have been grouped in disease sub-panels including leukemia, non-small-cell lung, 
colon, central nervous system, melanoma, ovarian, renal, prostate, and breast tumor 
cell lines (Table 1). The compounds were dissolved in dimethyl sulfoxide and 
evaluated at five concentrations at 10-fold dilution the highest being 10-4M and the 
others 10-5, 10-6, 10-7, and 10-8M18-20 in comparison with our lead compounds 1 and 2.  
Results showed in Table 1 are expressed as the negative log of the molar 
concentration at three assay end points: the 50% growth inhibitory power (pGI50), the 
cytostatic effect (pTGI = total growth inhibition), and the cytotoxic effect (pLC50). 
For several compounds this five concentration assay was repeated twice and no 
significative differences were found.  
Regarding compounds related to 1, we can observe that the removal of the methoxy 
group (7) or its shift to position 3, providing 3, caused a decrease of cytotoxic activity 
of more than ten folds, as, while its introduction in position 4 (5), restored completely 
the activity, which is comparable with that of the lead compound 1. The introduction 
of additional two methoxy groups in position 3 and 4 (19) or in 4 and 5 (21), caused a 
decrease in the cytotoxic activity in comparison with 1. 
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In the series of 2-related compounds, we can observe that the substitution of the 
methoxy group with a hydrogen (8) or fluorine (12) atom, did not cause any decrease 
in activity. On the contrary the presence of different substituents such as chlorine 
(10), nitro (14), trifluoromethyl (16) and methyl (18) groups in 2 position on the two 
aromatic rings determined a marked decrease of inhibitory activity on different cell 
lines in comparison with 2. In particular, it is to note that 16 did not show any 
significant activity up to 10 μM (Table 2). In this series the pattern of the multi-
substitution with three methoxygroups is different from that observed for 1-series. In 
fact compounds 20 and 22, characterized by 2,3,4 and 3,4,5 trimethoxysubstitution, 
respectively, showed different activity. In particular, 22 showed a decrease in 
inhibition activity in comparison with 2, on the contrary, 20 showed the highest levels 
of GI50 of the two series, emerging as the most potent derivative towards the different 
tested cell lines. Notably, this compound displayed the highest values of cytotoxic 
activity against the colon and prostate cells which are similar to those reported for 
vincristine, a well-known anticancer agent (see Table 1). These results indicated 20 as 
the most interesting derivative of the two series. Thus it was used as model compound 
for further investigations to elucidate its mechanism of action at cellular level.  
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Table 1. Growth Inhibition and Cytostatic and Cytotoxic Activity of 1-3, 5, 7, 8, 10, 
12, 19-22 in the 60-Cell Panel 
            
MG-
MIDb. 
Compda modes leukemia NSCLC colon CNS melanoma ovarian renal prostate breast 
           
1 pGI50 6.60 6.44 6.7 6.29 6.34 6.53 6.34 6.52 6.34 6.46 
 pTGI 6.17 6.07 6.35 5.89 5.95 6.05 5.92 6.02 5.88 6.03 
 pLC50 5.36 5.72 6.14 5.54 5.58 5.37 5.47 5.47 5.35 5.55 
2 pGI50 6.75 6.69 6.94 6.67 6.72 6.74 6.67 6.73 6.64 6.73 
 pTGI 6.10 6.26 6.51 6.23 6.41 6.08 6.27 6.36 6.19 6.27 
 pLC50 6.01 5.74 6.03 5.80 6.09 5.42 5.73 5.82 5.79 5.82 
3 pGI50 5.57 5.24 5.66 5.50 5.72 5.72 5.46 5.41 5.58 5.54 
 pTGI 5.05 4.98 5.30 5.04 5.42 5.42 5.04 4.76 5.13 5.13 
 pLC50  4.52 4.77 4.73 5.09 5.09 4.45 4.20 4.84 4.71 
5 pGI50 6.54 6.40 6.75 6.62 6.61 6.71 6.44 6.39 6.49 6.55 
 pTGI 5.83 5.79 6.28 5.96 6.22 6.06 5.91 5.78 5.98 5.98 
 pLC50 4.72 5.17 5.75 5.44 5.83 5.40 5.48 5.38 5.36 5.39 
7 pGI50 5.90 5.64 5.90 5.63 5.79 5.62 5.60 5.57 5.72 5.71 
 pTGI 5.30 5.20 5.57 5.04 5.44 5.24 5.21 4.94 5.24 5.24 
 pLC50  4.99 5.23 6.63 5.22 4.78 4.67  4.36 5.12 
8 pGI50 6.85 6.68 7.03 6.81 6.76 6.79 6.75 6.74 6.65 6.78 
 pTGI 6.05 6.23 6.53 6.42 6.44 6.30 6.29 6.37 6.16 6.31 
 pLC50  5.71 5.90 5.95 6.12 5.36 5.67 5.69 5.57 5.74 
10 pGI50 6.58 6.48 6.86 6.35 6.73 6.65 6.63 6.38 6.48 6.57 
 pTGI 5.79 5.96 6.37 5.86 6.13 6.15 6.15 5.88 6.03 6.03 
 pLC50 5.36 5.54 5.76 5.50 5.68 6.59 5.77 5.68 5.63 5.72 
12 pGI50 6.77 6.75 7.03 6.79 6.77 6.79 6.80 6,74 6.68 6.79 
 pTGI 5.88 6.36 6.56 6.42 6.44 6.31 6.42 6.35 6.20 6.33 
 pLC50 4.70 6.03 6.14 5.96 6.17 5.87 5.82 6.26 5.93 5.87 
19 pGI50 6.42 6.32 6.77 6.20 6.52 6.67 6.50 6.19 6.45 6.45 
 pTGI 5.93 5.85 6.33 5.74 6.09 6.49 6.26 5.91 5.94 6.06 
 pLC50  5.49 5.96 5.05 5.73 6.53 6.34  5.62 5.82 
20 pGI50 6.89 6.90 7.06 6.96 6.98 6.85 6.74 6.99 6.82 6.91 
 pTGI 6.22 6.48 6.64 6.57 6.68 6.43 6.36 6.63 6.38 6.49 
 pLC50 4.66 5.91 6.10 6.07 6.39 5.64 5.90 6.13 5.96 5.86 
21 pGI50 6.65 6.28 6.60 6.41 6.28 6.39 6.36 6.71 6.58 6.47 
 pTGI 6.29 5.92 6.02 5.94 6.01 6.04 6.09 6.13 6.20 6.07 
 pLC50  5.56 5.60 5.43 5.67 5.71 5.79 5.66 5.70 5.64 
22 pGI50 6.48 6.33 6.60 6.34 6.38 6.36 6.18 6.38 6.40 6.38 
 pTGI 5.71 5.86 6.08 5.85 5.98 5.77 5.73 5.87 5.89 5.86 
 pLC50 5.38 5.70 5.41 5.37 5.58 5.26 5.27 5.33 5.31 5.40 
vinc pGI50 7.00 6.60 7.00 6.90 6.80 6.50 6.50 6.90 6.50 6.74 
 pTGI 4.80 4.80 5.40 5.20 5.10 4.70 4.70 5.20 5.10 5.00 
 pLC50 3.20 3.60 4.10 3.70 3.60 3.50 3.60 3.50 3.50 3.59 
            
a1-3, 5, 7, 8, 10, 12, 19-22, di-p-toluensulfonate salts; highest concentration = 10-4M 
unless otherwise reported; only modes showing a value greater than 4.00 are reported. 
bMean graph midpoint, i.e., the mean concentration for all cell lines. cVincristine 
sulfate, highest concentration = 10-3 M. Data are expressed as the negative log of the 
molar concentration at three assay end points: the 50% growth inhibitory power 




Table 2. Cytotoxic Activity of 2, 14, 16, and 18 against HTLA-230, 
OVCAR-3, Mel 3.0, and SV620 Cells  
 pIC50
b 
compda HTLA OVCAR MZ2-Mel 3.0     SV620  MG/MIDd 
2 7.01 ± 0.31 6.70 ± 0.21 6.15 ± 0.07 6.40 ± 0.21   6.56 
14 6.04 ± 0.17 6.15 ± 0.29 5.77 ± 0.05 6.22 ± 0.24   6.05 
16 nac nac nac nac                 nac 
18 6.04 ± 0.19 5.71 ± 0.35 5.72 ± 0.16 6.04 ± 0.05   5.88 
adi-p-toluensulfonate salts. bIC50 values are the negative log of the molar 
concentration causing 50% growth inhibition, after 48 h of compounds 
exposure, evaluated by MTT method. cNot active at 10 µM. dMean graph 
midpoint, i.e., the mean concentration for all cell lines. Results, derived 
from three different experiments in quadruplicate wells as compared to 
that of control cells, are expressed as mean ± S.E.M. 
 
 
Effect of compound 20 on tumor cell proliferation. To give some insights into the 
biological effects of the novel compounds, the most potent derivative of the all series 
20 was further investigated in HeLa cells. It largely reduced cell survival (Figure 2A) 
with a IC50 value of 0.85 µM. Firstly, we determined whether it induced apoptosis. 
HeLa cells were treated with 20 for 24 h, afterward the activity of caspase proteases 
was assayed. Activation of caspase acting on the substrate sequence Asp-Glu-Val-Asp 
(DEVD), i.e. mainly effector caspases -3 and -7, represents a marker of apoptotic cell 
death.21 20 increased caspase activity in a dose-dependent manner (Figure 2B), in 
association to the increased number of cells committed to death. We then evaluated 
nuclear morphology, which is another reliable indicator of apoptotic cell death, by 
DAPI staining in cells treated for 24 h with 2 μM of 20 (Figure 2C). In 20-treated 
cells it was possible to detect several cells with characteristics of apoptosis, i.e. 





Figure 2. A. HeLa cells were incubated for 48 h in the presence of 20, then the 
number of alive viable cells was measured by dye exclusion. B. The cells were treated 
for 24 h with the indicated dose of 20, afterward, cells were collected for caspase 
activity determination. Data are mean ± S.E.M. of three replicates. C. Morphological 
evaluation of nuclei stained with DAPI from control HeLa cells and cells treated with 
2 µM of 20 for 24 h. 
 
Signal transduction pathway. We investigated the effect of 20 on signal 
transduction pathway involved in cell growth. In these studies, the cells were treated 
with 20 for 20 hours, then ERK1/2 mitogen-activated protein kinases that are 
generally associated with cell growth were examined. Figure 3 showed that 20 
downregulated the p44 ERK2 protein, and significantly inhibited the phosphorylation 
of both p42 and p44 ERKs, which are known to influence the survival of cancer 
cells.23  
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Figure 3. HeLa cells were incubated for 20 h in the presence of the indicated 
concentration of 20. The content and phosphorylation status of ERK 1/2 in cell 
extracts was determined by Western blotting (50 µg of protein/lane). 
 
In order to detect whether oxidative stress would play a role in the cytotoxic effects of 
the novel derivatives, we studied the effect of the antioxidant N-acetylcysteine 
(NAC). Figure 4 shows that NAC inhibited the toxic effect of 20, suggesting the 




Figure 4. Cell viability was measured in cells treated for 24 h with the indicated 
concentration of 20 in the absence or presence of 5 mM NAC. Results are mean ± 
S.E.M. of triplicate determinations. 
 
Effect of 20 on Cell Cycle Progression. To investigate whether the antiproliferative 
effect displayed by 20 was associated to a inhibition of cell cycle progression HTLA-
230 neuroblastoma cells were treated with 1.5 µM of 20 for 24-48 hours. The cells 
were then pulsed labelled with BrdU to examine DNA synthesis. As shown in Fig. 5, 
we observed a time-dependent increase of the proportion of cells in G2/M phases (R4) 
that was accompanied by a nearly complete depletion of cells in S phase (R3). In 
particular, the percentage of cells in S phase decreases from 33% to 9.6% while the 
percentage of cells accumulated in G2/M phases was of 30% after 48 h of treatment. 
Moreover, the percentage of cells in the sub-G1 fraction (R1), which contains 
apoptotic cells, increased at longer times of 20 exposure (from 0.9% to 15.2% after 48 
h). Therefore the cell cycle analysis showed a concomitant rise of treated cells in  
G2/M fraction and a depletion of S fraction. These findings suggest delay in exit of 
daughter cells from the mitotic cycle leading to reduction of tumor cell number. 
 
Figure 5. Effect of 20 on cell cycle progression in HTLA-230 neuroblastoma cells. 
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HTLA-230 were exposed to 1.5 µM of 20 for the indicated times and then the cells 
were analysed for DNA synthesis by pulse labelling with bromodeoxyuridine. BrdU 
uptake (fluorescein isothiocynate, y-axis) versus total cellular DNA content 
(propidium iodide, x-axis) was evaluated by densitometric fluorescence-activated cell 
sorter analysis.(R1 = sub-G1-phase cells; R2 = G1-phase cells; R3 = S-phase cells; R4 
= G2/M-phase cells). 
Annexin V flow cytometric analysis of apoptosis. We evaluated the apoptosis in 
OVCAR 3.0 cells treated with 20 by staining cells with Annexin V-FITC and PI, 
FACS was used to distinguish and quantitatively determine the percentage of dead, 
viable, apoptotic and necrotic cells. As shown in Figure 6 panel A, OVCAR 3.0 
control and treated cells were gated into LR (Lower Right), UP (Upper Right), LL 
(Lower Left) and UL (Upper Left) quadrants. Cells in LR and UR were considered as 
early apoptotic (annexin+/PI-) and late apoptotic (annexin+/PI+) respectively. Cells in 
LL and UL were considered live (annexin-/PI-) and necrotic (annexin+/PI+)  
respectively. We reported the most representative experiment after 72 h of drug 
exposure: the percentage of total apoptosis recorded in treated cells was 41% at 1.5 
µM, 47% at 2.0 µM and 57% at 2.5 µM. These data confirmed the apoptotic mode of 
cell death. The experiment was repeated three times with similar results.  
In Figure 6 panel B the extent of apoptosis was expressed as the sum of the 
percentages in LR and UR quadrants. Compound 20  was effective in inducing 
apoptosis in a dose and time dependent manner. The mean values and standard 
deviations calculated for untreated and treated cells at different concentrations in 
combination with the statistical analysis determined by Mann Whitney test 
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demonstrated that the differences between control and treated cells are statistically 














Figure 6. (A) Representative flow cytometry analysis of apoptosis induced by 20 at 
different concentrations in OVCAR 3.0 ovarian carcinoma cell line after 72 h of drug 
exposure, using annexin V-FITC/PI double staining method. Quadrant analysis of 
fluorescence intensity of gated cells in FL-1 (annexin V-FITC) and FL-3 (PI) 
channels was from 10,000 events.  The lower left quadrant shows viable cells; the 
lower right quadrant shows viable cells in early stages of apoptosis; the upper right 
quadrant shows cells in the later stage of apoptosis; and the upper lower left quadrant 
shows dead cells. (B) Quantitative detection of 20-induced apoptosis by Annexin V-













































columns: control; light grey columns: 20 compound 1.5 µM; grey columns: 20 
compound 2.0 µM; black columns: 20 compound 2.5 µM. Bars represent the mean 
number of triplicates wells from three independent experiments; statistical 
significance of differences between untreated and treated groups at different times 
was determined by Mann-Whitney test., two tailed, with 95% confidence intervals. * 
P = 0.0286 vs controls. 
 
Tubuline Assays. As above reported, derivatives 19-22 were designed by introducing 
the trimethoxyphenyl pharmacophore, peculiar of some anticancer agents such as 
colchicine, podophyllotoxin and combrestatin A4 which affect the microtubules 
structure, with the aim to hit this specific and important biological target.  
 
 
Figure 7. Effect of 19-22 and reference compound 2 on the cytoplasmic microtubule 
network of A549 lung carcinoma cells. A549 cells were incubated for 20 hours with 
either A, DMSO, B, 10 µM 20, C, 50 µM 19, D, 50 µM 21, E, 20 µM 22,or F, 20 µM 
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2. Microtubules were stained with anti-tubulin monoclonal antibodies (DM1A). The 
bar is 10 µm. 
 
To verify this interesting biological activity 19-22 and the reference compound 2 were 
tested both in cells and in vitro assays. Concerning the first series of assays, A549 
cells were incubated for 20 hours with 100 times the GI50 of 19-22 and 2. In these 
experiments no depolimerization of the cytoplasmic microtubules was observed 
(Figure 7). In particular, when the cells were treated with 21 and 2 (Figure 7, D, F) the 
cells became rounded and the microtubule cytoskeleton looked disorganized but no 
microtubule depolimerization was observed. As control 2.5 µM podophilotoxin was 
employed and the cellular microtubules completely depolimerized (results not 
shown).  
Concerning the in vitro assay we tested the assembly of 25 uM tubulin in the presence 
of 30 μM of 2, 19-21. In the absence of compounds the critical concentration of 
tubulin required for assembly was 3,40 ± 0.83 uM. In the presence of a stabilizer 
(docetaxel) the concentration was of course lower 1,24 ± 0.31 uM. In the presence of 
a destabiilizer (podofilotoxin) the concentration required is lower 7.40 ± 0.79 μM. In 
the presence of the compounds 2, 19-21 the required concentration was equal to those 
required in the absence of drug 3.67 ± 0.90 3.65 ± 0.97 3.23 ± 0.86 3.50 ± 1.09, 
respectively, and no effect on tubulin assembly was observed. 
These results demonstrated that 2, 19-21 did not affect directly microtubules and 
tubulin. In particular, in A549 cells they were cytotoxic but they did not impair 
microtubules functions.  
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DNA-Binding properties. Several NDI derivatives are efficient DNA binders and 
this property can result in promotion of cell apoptosis. To preliminary assess the 
ability of the most interesting compounds of the 2 series (8, 12, 20 and 22) to interact 
with double stranded DNA, a fluorometric intercalator displacement method was 
applied.24 DNA-binding activity was expressed as the drug concentration able to 
reducing by 50% the fluorescence of DNA-bound ethidium bromide (EtBr) 
Displacement. This EC50 value allows to estimate the affinity ranking order of the 
ligands for calf thymus DNA.24, 25 All tested derivatives turned out to be strong DNA-




Table 3. DNA Binding of 1, 2, 8, 12, 20 and 22 evaluated by EtBr Displacement and 
fluorescence quenching determined at 2.5 M ligands concentration. 
 
 





Compound ctDNA G4 dsDNA 
1 93 ± 4c 16.1 6.2 
2  122 ± 6 c 15.5 7.7 
8 118 ± 8 18.5 11.3 
12 130 ± 8 16.4 8.1 
20 166 ± 8 20.5 8.4 
22 159 ± 8 16.1 5.2 
aEC50 values are defined as the drug concentrations which reduce the fluorescence of 
the DNA-bound ethidium by 50%. bTm corresponds to the increment in the DNA 
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Figure 8. Variation of DNA (0.25 μM) thermal stability (Tm) produced by tested 
ligands in 50 mM potassium buffer, pH 7.4, evaluated by fluorescence quenching 
experiments. Heating rate 1 °C/min. PANEL A: increasing concentration of 20 on 
G-quadruplex DNA; PANEL B: 2, 8, 12, 20, and 22 (2.5 M) on G-quadruplex 
(black bars) and dsDNA (grey bars).  
Additionally, as reported in the literature, NDI derivatives can selectively interact 
with differently folded DNA structures accordingly to their substitution pattern and 
the nature of the side chains. Thus, the G-quadruplex and duplex DNA recognition of 
the selected NDI were compared by fluorescence quencing assay using a G-
quadruplex folded sequence based on the human telomeric sequence (G4) and a 
random double stranded DNA (dsDNA). All derivatives were able to significantly 
increase the tested DNAs melting temperatures in a concentration dependent manner 
(Figure 8). It emerged that the increment in the melting temperature was generally 
more intense for the G-quadruplex folded sequence then for the dsDNA template. 
However, on both substrates, the process appeared to reach saturation in the low 
micromolar range, which suggests a strong interaction with both DNA arrangements. 
In Table 3 we report the shift in the DNA melting temperature induced by 2.5 M 
 20 
ligands concentration that confirmed modest efficiency variation among the tested 
compounds, in particular toward the G-quadruplex structure. However, 20 appears to 
be the most efficient G-quadruplex binder whereas 8, in agreement with FID data, 
induced the most relevant stabilization on double stranded DNA. The difference 
between the recognition of the two DNA foldings slightly increments accordingly 
with the number of methoxy groups whereas, their substitution with a fluorine atom 
(12) does not significantly alter the DNA stabilization properties which parallels the 
cytotoxic effect.  
The interaction of all derivatives with both substrates was further confirmed by CD 
spectroscopy. As reported in Figure 8, when NDI derivatives 2, 8, 12, 20, and 22 were 
added to a double stranded DNA an increment of the intensities of the two mayor 
bands located at 275 and 245 nm occurred. This confirms an intercalation binding 
mode for NDI into the double helix. When the substrate was the human telomeric G-
quadruplex the binding of the ligand induced an increment of intensity of the 295 
band which is generally attributed to the antiparralel components of the nucleic acid 






















Figure 9. Modification of DNA CD spectra upon addition of 20 (0-20 M) in 10 mM 
Tris, 50 mM KCl, pH 7.5. Arrows indicate spectrals changes upon ligand addition. 
Panel A: 4 M Tel22, panel B, 45 M ctDNA.  
 
To get further insight into the NDI derivatives-DNA interaction, we performed a 
quantitative analysis of the binding process towards the two substrates using 20 as 
model compound. These data were obtained accoding UV-VIS titrations since 
addition of dsDNA or G-quadruplex DNA induced a significative reduction of the 
drug absorbance (Figure 10). The results of such an analysis are summarized in Table 
4. These confirmed a relevant affinity of 20 toward both DNA substrates: the 
difference in Ka is likely not sufficient to preclude the recognition of one target in 
physiological conditions.  
From these data we can additionally confirm that staking interactions are relevant for 
the DNA binding process. Indeed, dsDNA binding data analysis indicated a complex 
stoichimetry (n) of two base pairs for each bound drug molecule, which is in line with 
an intercalation binding mode. In the presence of G-quadruplex, we found two NDI 
molecules bound to one DNA structure. This likely corresponds to the staking of the 
ligands on each terminal tetrads. 
 
Table 4. Thermodynamic parameters for the DNA binding by 20 determined in 10 
mM Tris, 20 mM KCl, pH 7.5, 37°C. n refears to the number of G-quadruplex or base 
pairs involved in the binding of one NDI molecule. 
 
 Ka·10-6 (M-1) n 
G-quadruplex 6.94  ± 2.05 0.49 ± 0.01 




Merging these results, we can infer that by incrementing the number of the methoxy 
groups on the side chains, the insertion of the aromatic portion (NDI core) between 
two base pairs of the double helix can be hindered. Indeed steric effect can occur to 
impair thereading of one side chain between two base pairs. On the opposite, this 
structural feature should not sensibly affect the staking mode of the NDI on the 
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Figure 10. Titrations of 20 (10-20 μM) with DNA in 10 mM Tris, 50 mM KCl, pH 
7.5. PANEL A: human telomeric sequence folded in G-quadruplex; PANEL B: 
ctDNA. Arrows indicate absorption spectra change upon DNA addition. 
 
Taq Polymerase and Telomerase Inhibition Assays. Derivatives 1, 2, 8, 12, 20, and 
22 were evaluated for their inhibitory activity on Taq Polymerase. The most potent 
derivative was 22, with 2 and 20 slightly less potent, but in the same order. 
Interestingly, 1 and 12, characterized by shorter side chains and by a fluorine atom on 































the aromatic rings, respectively, were the less potent of the all series, showing no 
activity up to 40 M. 
Since test derivatives showed to be able to recognize also telomeric G-quadruplex 
sequences, we additionally evaluated telomerase activity in HeLa cells treated with 
20, the best G-quadruplex binder. Our results confirmed that the tested NDI is able to 
reduce the activity of this enzyme thus confirming a cytotoxic mechanism which can 





Figure 11. Reduction of telomerase activity in HeLa cell after treatment for 24 h with 
20. For each line, a cellular extract corresponding to 2 ng of total proteins was used.   
 
Molecular modelling studies. 
The most interesting compound 20 of the novel NDI series has been submitted to 
molecular modelling calculations with the aim to characterize its conformational 
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profile and to propose binding modes against the DNA target, accordingly to the 
experimental evidences.  
Firstly, the ionization state of 20 has been analyzed with respect to the 
thermodynamic experimental conditions (pH = 7.5). Such an analysis was carried out 
by the program LigPrep.26 The bis cationic form, with both secondary amines 
protonated, was indicated as the most prevalent among all ionisable states. 
Secondly, in this ionization form, the conformational study has been carried out by 
the Monte Carlo search, as implemented in the MacroModel (version 9.0, 2009)27 
generating 10000 conformations and energy minimizing them by the AMBER* force 
field28 with the united atom notation and the GB/SA water solvation model.29 The 
number of conformers found within 5 kcal/mol above the global minimum was equal 
to 81.  
Thirdly, the docking experiments were carried out selecting the DNA target models 
from the Protein Data Bank (PDB).30 The selection of the DNA duplex model was 
performed by the analysis of intercalative ligands with resolution factor equal or 
lower than 1.5 Å. The PDB entry 1Z3F contains two guanine-citosine intercalative 
binding sites and the ligand (ellipticine) characterized by an extended aromatic core.31 
It was selected as template model for the DNA duplex docking. 
As concerns the PDB G-quadruplex models, the availability of an NDI derivative co-
crystal with the human telomeric sequence, led us to select as reference template 
model the 3CDM entry.32  
Both duplex and G-quadruplex PDB entries were prepared for the docking 
eliminating non nucleic acid components, such as ligands, counterions and water 
molecules, included into the original models. As concerns the 3CDM entry, based on 
two DNA dimer subunits, both A and B chains were considered for the docking 
simulations.  
The docking with the duplex DNA model was performed following the computational 
approach successfully tested with intercalative moieties in other antitumor 
compounds.33 The target DNA was isolated in a conformation able to give 
intercalative recognition with ligands by stacking and groove interactions. 
Accordingly to our last reported experiments we have considered two computational 
protocols based on Autodock34 and Moline35 docking programs. In both cases, 
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accordingly to the Moline general protocol36 and to reported case studies,37, 38 the best 
poses were submitted to full energy optimization in the same conditions used for the 
conformational search of the isolated compound 20. The ensembles of optimized 
poses were then submitted to the estimation of free energy of complexation at room 
temperature. 
The docking models obtained with Autodock were able to lead to energy minima 
lower than those with Moline. So we have analyzed them in details in order to 
characterize the recognition of 20 against the duplex and the quadruplex DNA 
conformations. The results of the Autodock optimized poses in terms of free energy of 
complexation are in agreement with the thermodynamic data reported in Table 4. 
Compound 20 docked with the DNA duplex model gave free energy of complexation 
equal to -92.2 kcal/mol, and with A and B G-quadruplex conformations values 
respectively equal to -66.2 and -79.3 kcal/mol. The reason of the high stability found 
with the DNA duplex can be understood analyzing the lowest energy pose reported in 
Figure 12, constructed by the LigandScout software.39 There is a synergy of attractive 
interactions due to the NDI core stacking (two contributions) within the guanine-
citosine intercalation site, one hydrophobic contact and hydrogen bond within the 
minor groove and two hydrogen bonds within the major groove. One of this last 
contributions is due to the m-methoxyl group of one side chain. 
Conversely, the molecular recognition obtained in the docking simulations with the 
DNA G-quadruplex model was based in the best pose on few attractive contributions, 
as shown in Figure 13. Only one stacking interaction exerted by to one 
trimetoxyphenyl moiety was detected with the 8th nucleic residue (adenosine) located 
in a loop region of the target DNA G-quadruplex. The ligand established one 
hydrogen bond only with the 21st nucleotide (guanosine). The NDI core was not able 
to establish a proper end-stacking interaction with the G-quarter core in “top” or 
“bottom” sites, as classified in our previous communication.40 The presence of the 
bulky trimethoxy sidechains likely prevented a good fit of the NDI core, as it happens 
with the ligand co-crystallized in the reference 3CMD PDB model. Moreover, the 
structure of 20 in the best pose highlights a certain difficulty to assume, into the 
binding region of the DNA G-quadruplex, an extended conformation, that can be 
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considered as a qualitative indicator of the steric hindrance in the recognition against 
this target. 
In conclusion the docking experiments proposed different binding modes of 
interaction of 20 against duplex and G-quadruplex DNA models. The reason of a 
better recognition against the first target was justified in terms of superior non-
covalent contributions and better fit properties of the ligand. The NDI core was able 
to establish stacking interactions via intercalative recognition with the duplex DNA 
only. The steric hindrance of the trimethoxy benzylamino propyl sidechains prevented 






Figure 12. a) 3D representation of the compound 20 best intercalative pose within the 
DNA duplex. The ligand and the DNA are respectively displayed as polytube and 
wireframe models. The gray surface represents target binding pocket. The 
hydrophobic features of the ligand are pointed as yellow spheres. The exclusion 
volume coats onto the target are shown as gray spheres. Intermolecular hydrogen 
bonds are displayed as red and green arrows, pointing respectively ligand acceptor 
and donor atoms. Positive ionizable target nitrogens are shown as blue features. The 
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ligand aromatic rings detected to interact via π-π interactions are highlighted with 
blue circles with top/bottom triangles. 
b) 2D ligand representation with the main interaction features with the DNA duplex 
model. Three intermolecular hydrogen bonds are represented by dotted vectors. 
Electrostatic interacting nitrogens are shown as blue features. Hydrophobic interacting 
rings are highlighted in yellow. NDI core π-π stacked rings are depicted with blue 
circles and black arrows. The top ruler indicates the corresponding DNA duplex 




Figure 13. a) 3D representation of compound 20 best pose obtained with the DNA G-
quadruplex model (PDB entry 3CDM chain B). The ligand and the DNA are 
respectively displayed as polytube and wireframe models. The gray surface represents 
target binding pocket. The exclusion volume coats onto the target are shown as gray 
spheres. The intermolecular donating hydrogen bond is displayed as green arrow. 
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Positive ionizable target nitrogens are shown as blue features. The ligand aromatic 
ring detected to interact via π-π interactions is highlighted with a blue circles with 
top/bottom triangles. 
b) 2D ligand representation with the main interaction features with the DNA G-
quadruplex model. One intermolecular hydrogen bond is represented by a dotted 
vector. Electrostatic interacting nitrogens are shown as blue features. The π-π stacked 
ring is depicted with blue circles and a black arrow.  
 
Conclusion 
The present article expands on the study of the structure-activity relationships of the 
prototypes 1 and 2, especially by investigating the role of the substituents on the two 
aromatic rings included in the side chains. The cytostatic and cytotoxic activities of 1 
and 2 were affected by the insertion of different substituents on the two aromatic rings 
confirming a their possible influence on the biological effects. Derivative 20, 
characterized by a chain length of three methylene units and by 2,3,4-trimethoxy 
groups on the two aromatic rings, was the most potent of the all series showing an 
interesting biological profile. In fact, it displayed pGI50 values around 7, 
demonstrating an improvement of the cytotoxic activity towards multiple cancer lines, 
in comparison with lead compounds 1 and 2 and comparable with those of vincristine. 
Nevertheless, the mechanism of action of 20 is distinct from vincristine. Indeed, 20 
showed the ability to tightly bind DNA, to inhibit Taq polymerase and telomerase, to 
trigger caspase activation by a possible oxidative mechanism, to downregulate ERK 2 
protein and to inhibit ERKs phosphorylation, without acting directly on microtubules 
and tubuline.  
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According to these promising results, this compound might be considered a 
multitarget anticancer agent and a promising starting point for designing new 
antiproliferative agents.  
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(A) Chemistry. All the synthesized compound have a purity of at least 95% 
determined by HPLC analysis. Melting point were taken in glass capillary tubes on a 
Buchi SMP-20 apparatus and are uncorrected. ESI-MS spectra were recorded on 
Perkin-Elmer 297 and WatersZQ 4000. 1H NMR and 13C NMR were recorded on 
Varian VRX 200 and 400 instruments. Chemical shift are reported in parts per 
millions (ppm) relative to peak of tetramethylsilane (TMS) and spin multiplicities are 
given as s (singlet), brs (broad singlet), d (doublet), t (triplet), q (quartet) or m 
(multiplet) Although IR spectral data are not included (because of the lack of unusual 
features), they were obtained for all compounds reported, and they were consistent 
with the assigned structures. The elemental analysis was performed with Perkin Elmer 
elemental analyzer 2400 CHN. From all new compounds satisfactory elemental 
analyses were obtained, confirming >95%purity. Chromatographic separations were 
performed on silica gel columns by flash (Kieselgel 40, 0.040-0.063 mm, Merck) 
column chromatography. Reactions were followed by thin layer chromatography 
(TLC) on Merck (0.25 mm) glass-packed precoated silica gel plates (60 F254) and 
then visualized in an iodine chamber or with a UV lamp. The term “dried” refers to 
the use of anhydrous sodium sulphate.  
General Procedure for the Synthesis of 3-22: a mixture of the appropriate amine 
23-42 and 1,4,5,8-Naphthalene-tetracarbocylic dianhydride in a 1:5 molar ratio in iso-
propanol were refluxed for 2 hours. After cooling down, removal of the solvent gave 
residue that was purified by flash chromatography using as eluent a mixture of 
dichloromethane/methanol/acqueous 33% ammonia (9:1:0.03) providing the desired 
products 3-22 that were converted into the corresponding di-p-toluenesulfonates salt. 
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2,7-Bis-[2-(3-methoxy-benzylamino)-ethyl]-benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone (3): yellow oil; 28% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 
1.58 (brs, 2H exchangeable with D2O), 3.06 (t, 4H, J = 6.2), 3.76 (s, 6H), 3.84 (s, 4H), 
4.41 (t, 4 H, J = 6.2), 6.85-6.89 (m, 4H), 7.18-7.29 (m, 4H), 8.78 (s, 4H); mp (di-
paratoluensulfonates salt) 152-155°C, MS (ESI+) m/z = 593 (M +H)+. Anal. 
(C48H48N4O12S2 · 2H2O), C, H, N. 
2,7-Bis-[3-(3-methoxy-benzylamino)-propyl]-benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone (4): yellow oil; 16% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 
1.99-2.10 (m, 4H + 2H exchangeable with D2O), 2,77 (t, 4H, J = 6.6), 3.81 (s, 10H), 
4.34 (t, 4H, J = 7.7), 6.75-6.80 (m, 2H), 6.88-6.92 (m, 4H), 7.17-7.25 (m, 2H), 8.76 
(s, 4H); 13C NMR (50MHz, CDCl3) δ 28.2, 39.0, 46.5, 53.8, 55.3, 112.4, 113.7, 120.5, 
126.6, 128.0, 129.4, 131.1, 158.7, 163.8; mp (di-paratoluensulfonates salt) 102-
104°C; MS (ESI+) m/z = 621 (M +H)+. Anal. (C50H52N4O12S2 · 2H2O), C, H, N. 
2,7-Bis-[2-(4-methoxy-benzylamino)-ethyl]-benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone (5): yellow oil, 15.0 % yield; 1H NMR (free base, 400 MHz, CDCl3) 
δ 1.54 (brs, 2H exchangeable with D2O), 3.02 (t, 4H, J = 6.4), 3.74 (s, 6H); 3.76 (s, 
4H); 4.37 (t, 4H, J = 6.4); 6.74-6.76 (m, 4H); 7.16-7.18 (m, 4H); 8.75 (s, 4H), mp (di-
paratoluensulfonates salt) 124-126°C; MS (ESI+) m/z = 593 (M +H)+. Anal. 
(C48H48N4O12S2 · 2H2O), C, H, N. 
2,7-Bis-[3-(4-methoxy-benzylamino)-propyl]-benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone (6): yellow oil; 21% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 
1.59 (brs, 2H exchangeable with D2O), 2.00 (m, 4H), 2.75 (t, 4H, J = 6.4), 3.75 (s, 
4H), 3.79 (s, 6H), 4.32 (t, 4H, J = 7.0), 6.80-6.84 (m, 4H), 7.20-7.28 (m, 4H), 8.77 (s, 
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4H); mp (di-paratoluensulfonates salt) 134-136°C; MS (ESI+) m/z = 621 (M +H)+. 
Anal. (C50H52N4O12S2 · 2H2O), C, H, N. 
2,7-Bis-(2-benzylamino-ethyl)-benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone 
(7): yellow oil; 30% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 1.58 (brs, 2H 
exchangeable with D2O); 3.07 (t, 4H, J = 6.2), 3.88 (s, 4H), 4.42 (t, 4H, J = 6.6), 7.23-
7.29 (m, 10H), 8.79 (s, 4H); 13C NMR (50 MHz, CDCl3) δ 40.6, 46.9, 53.6, 126.7, 
127.0, 128.2, 128.5, 131.1, 151.1, 152.0, 163.2; mp (di-paratoluensulfonates salt) 163-
165°C; MS (ESI+) m/z = 533 (M +H)+. Anal. (C46H44N4O10S2 · 2H2O), C, H, N. 
2,7-Bis-(3-benzylamino-propyl)-benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone 
(8): yellow oil; 34% yield; 1H NMR (free base, 200 MHz, CDCl3) δ1.45-1.45 (m, 2H 
+ 4H exchangeable with D2O), 3.15 (t, 4H, J = 6.2), 3.76 (s, 4H), 4.32 (t, 4H, J = 6.6), 
7.17-7.25 (m, 10H), 8.72 (s, 4H); mp (di-paratoluensulfonates salt) 163-165°C; MS 
(ESI+) m/z = 561 (M +H)+. Anal. (C48H48N4O10S2 · 2H2O), C, H, N. 
2,7-Bis-[2-(2-chloro-benzylamino)-ethyl]-benzo[lmn][3,8]phenanthroline-1,3,6,8-
tetraone (9): yellow oil; 35% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 1.61 
(brs, 2H exchangeable with D2O), 3.06 (t, 4H, J = 6.6), 3.97 (s, 4H), 4.42 (t, 4H, J = 
6.6), 7.17-7.19 (m, 4H), 7.28-7.35 (m, 4H), 8.78 (s, 4H); mp (di-paratoluensulfonates 
salt) 174°C; MS (ESI+) m/z = 601 (M +H)+. Anal. (C46H42Cl2N4O10S2 · 2H2O), C, H, 
N. 
2,7-Bis-[3-(2-chloro-benzylamino)-propyl]-benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone (10): yellow oil; 21% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 
1.69 (brs, 2H exchangeable with D2O), 1.95-2.08 (m, 4H), 2.78 (t, 4H, J = 7.0), 3.90 
(s, 4H), 4.34 (t, 4H, J = 7.0), 7.16-7.24 (m, 4H), 7.28-7.40 (m, 4H), 8.76 (s, 4H); 13C 
NMR (50 MHz, CDCl3) δ 28.4, 39.1, 46.6, 51.2, 126.7, 126.8, 128.3, 129.5, 130.1, 
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131.0, 133.8, 137.7, 151.2, 163.0; mp (di-paratoluensulfonates salt) 115°C; MS (ESI+) 
m/z = 629 (M +H)+. Anal. (C48H44Cl2N4O10S2 · 2H2O), C, H, N. 
2,7-Bis-[2-(2-fluoro-benzylamino)-ethyl]-benzo[lmn][3,8]phenanthroline-1,3,6,8-
tetraone (11): yellow oil; 27% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 1.62 
(brs, 2H exchangeable with D2O), 3.06 (t, 4H, J = 6.2), 3.85 (s, 4H), 4.41 (t, 4H, J = 
6.2), 6.95-7.05 (m, 8H), 8.78 (s, 4H); mp (di-paratoluensulfonates salt) 174°C dec; 
MS (ESI+) m/z = 569 (M +H)+. Anal. (C46H44F2N4O10S2 · 2H2O), C, H, N. 
2,7-Bis-[3-(2-fluoro-benzylamino)-propyl]-benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone (12): yellow oil; 22% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 
1.73 (brs, 2H exchangeable with D2O), 1.90-2.08 (m, 4H), 2.77 (t, 4H, J = 7.0), 3.87 
(s, 4H), 4.33 (t, 4H, J = 7.4), 6.97-7.21 (m, 4H), 7.23-7.37 (m, 4H), 8.76 (s, 4H); 13C 
NMR (50 MHz, CDCl3) δ 28.3, 39.0, 46.5, 47.3, 115.5, 124.1, 126.7, 128.6, 128.8, 
130.4, 130.5, 131.01, 151.1, 163.0; mp (di-paratoluensulfonates salt) 104-107°C; MS 
(ESI+) m/z = 597 (M +H)+. Anal. (C48H46F2N4O10S2 · 2H2O), C, H, N. 
2,7-Bis-[2-(2-nitro-benzylamino)-ethyl]-benzo[lmn][3,8]phenanthroline-1,3,6,8-
tetraone (13): yellow oil; 26% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 1.62 
(brs, 2H exchangeable with D2O), 3.08 (t, 4H, J = 6.2), 4.11 (s, 4H), 4.41 (t, 4H, J = 
6.2), 7.28-7.54 (m, 6H), 7.80-7.85 (m, 2H), 8.78 (s, 4H); 13C NMR (50 MHz, CDCl3) 
δ 40.3, 47.1, 50.6, 124.7, 126.7, 128.1, 131.0, 131.3, 133.0, 135.4, 149.3, 151.3, 
163.2; mp (di-paratoluensulfonates salt) > 250°C; MS (ESI+) m/z = 623 (M +H)+. 
Anal. (C46H42N6O14S2 · 2H2O), C, H, N. 
2,7-Bis-[3-(2-nitro-benzylamino)-propyl]-benzo[lmn][3,8]phenanthroline-1,3,6,8-
tetraone (14): yellow oil; 24% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 1.83 
(brs, 2H exchangeable with D2O), 1.85-1.97 (M, 4H), 2.77 (t, 4H, J = 6.6), 4.06 (s, 
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4H), 4.32 (t, 4H, J = 7.0), 7.36-7.44 (m, 2H), 7.53-7.66 (m, 4H), 7.92-7.96 (m, 2H), 
8.74 (s, 4H); 13C NMR (50 MHz, CDCl3) δ 28.4, 39.0, 46.9, 50.8, 124.8, 126.6, 128.0, 
131.1, 131.3, 133.2, 135.7, 149.2, 163.0; mp (di-paratoluensulfonates salt) 90-95°C; 
MS (ESI+) m/z = 651 (M +H)+. Anal. (C48H46N6O14S2 · 2H2O), C, H, N. 
2,7-Bis-[2-(2-trifluoromethyl-benzylamino)-ethyl]-
benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone (15): yellow oil; 25% yield; 1H 
NMR (free base, 200 MHz, CDCl3) δ 1.59 (brs, 2H exchangeable with D2O), 3.08 (t, 
4H, J = 6.2), 4.03 (s, 4H), 4.43 (t, 4H, J = 6.2), 7.21-7.63 (m, 8H), 8.79 (s, 4H); 13C 
NMR (50 MHz, CDCl3) δ 40.4, 47.1, 49.6, 103.2, 125.9, 126.0, 126.7, 127.0, 128.3, 
130.2, 131.1, 131.9, 138.8, 163.1; mp (di-paratoluensulfonates salt) 122-126°C; MS 
(ESI+) m/z = 669 (M +H)+. Anal. (C48H42F6N4O14S2 · 2H2O), C, H, N 
2,7-Bis-[3-(2-trifluoromethyl-benzylamino)-propyl]-
benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone (16): yellow oil; 27% yield; 1H 
NMR (free base, 200 MHz, CDCl3) δ 1.58 (brs, 2H exchangeable with D2O), 2.02 (m, 
4H), 2.81 (t, 4H, J = 7.0), 3.98 (s, 4H), 4.35 (t, 4H, J = 6.2), 7.29-7.38 (m, 2H), 7.47-
7.55 (m, 2H), 7.62-7.65 (m, 4H), 8.78 (s, 4H); mp (di-paratoluensulfonates salt) 119-
121°C; MS (ESI+) m/z = 697 (M +H)+. Anal. (C50H46F6N4O14S2 · 2H2O), C, H, N 
2,7-Bis-[2-(2-methyl-benzylamino)-ethyl]-benzo[lmn][3,8]phenanthroline-1,3,6,8-
tetraone (17): yellow oil; 28% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 1.53 
(brs, 2H xchangeable with D2O), 2.27 (s, 6H), 3.08 (t, 4H, J = 6.4), 3.82 (s, 4H), 4.39 
(t, 4H, J = 6.4), 7.05-7.08 (m, 5H), 7.21-7.26 (m, 3H), 8.74 (s, 4H); 13C NMR 
(50MHz, CDCl3) δ 19.2, 40.7, 47.3, 51.5, 126.0, 126.8, 1267.0, 127.1, 128.6, 130.4, 
131.2, 136.5, 138.3, 163.3; mp (di-paratoluensulfonates salt) 149-151°C; MS (ESI+) 
m/z = 561 (M +H)+. Anal. (C48H48N4O10S2 · 2H2O), C, H, N 
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2,7-Bis-[3-(2-methyl-benzylamino)-propyl]-benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone (18): yellow oil; 37% yield; 1H NMR (free base, 200 MHz, CDCl3) δ 
1.64 (brs, 2H exchangeable with D2O), 2.03 (m, 4H), 2.37 (s, 6H), 2.83 (t, 4H, J = 
7.0), 3.80 (s, 4 H), 4.34 (t, 4H, J = 7.0), 7.14-7.15 (m, 5H), 7.25-7.28 (m, 3H), 8.76 (s, 
4H); 13C NMR (50 MHz, CDCl3) δ 18.9, 28.2, 39.0, 46.9, 51.4, 125.7, 126.4, 126.5, 
126.8, 128.2, 130.1, 130.8, 136.2, 138.1, 162.8; mp (di-paratoluensulfonates salt) 137-
140°C; MS (ESI+) m/z = 589 (M +H)+. Anal.(C50H52N4O10S2 · 2H2O), C, H, N 
2,7-Bis-[2-(2,3,4-trimethoxy-benzylamino)-ethyl]-
benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone (19): yellow oil; 27% yield; 1H 
NMR (free base, 400 MHz, CDCl3) δ 1.90 (brs, 2H exchangeable with D2O), 3.01 (t, 
4H, J = 12.8), 3.49-3.90 (m, 22H), 4.38 (t, 4H, J = 8.7), 6.56-6.58 (d, 2H, J = 8.4), 
6.92-6.94 ( d, 2H, J = 8.4), 8.75 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 40.1, 46.4, 
48.4, 50.2, 55.8, 60.6, 106.8, 124.1, 125.2, 126.5, 126.6, 130.7, 141.9, 151.9, 153.0, 
163.2; mp (di-paratoluensulfonates salt) 237°C dec; MS (ESI+) m/z = 735 (M +Na)+. 
Anal.(C52H56N4O16S2 · 2H2O), C, H, N 
2,7-Bis-[3-(2,3,4-trimethoxy-benzylamino)-propyl]-
benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone (20): yellow oil; 46% yield; 1H 
NMR (free base, 400 MHz, CDCl3) δ 1.96-2.0 (m, 4H + 2H exchangeable with D2O), 
2.74 (t, 4H, J = 8.0), 3.73 (s, 4H), 3.82 (s, 6H), 3.84 (s, 6H), 3.90 (s, 6H), 4.29 (t, 4H, 
J = 8.0), 6.56-6.58 (d, 2H, J = 8.0), 6.92-6.94 (d, 2H, J = 8.0), 8.73 (s, 4H); 13C NMR 
(100 MHz, CDCl3) δ 28.1, 38.9, 46.4, 48.4, 55.8, 60.6, 60.9, 106.8, 123.9, 125.7, 
126.3, 126.4, 130.7, 141.9, 151.9, 152.8, 162.6; mp (di-paratoluensulfonates salt) 
237°C dec; MS (ESI+) m/z = 741 (M +H)+. Anal.(C54H60N4O16S2 · 2H2O), C, H, N 
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2,7-Bis-[2-(3,4,5-trimethoxy-benzylamino)-ethyl]-benzo[lmn][3,8]phenanthroline 
-1,3,6,8-tetraone (21): yellow oil; 39% yield; 1H NMR (free base, 200 MHz, CDCl3) 
δ 1.52 (brs, 2H exchangeable with D2O), 3.04 (t, 4H, J = 6.4), 3.74-3.80 (m, 22H), 
4.38 (t, 4H, J = 6.3), 6.52 (s, 4H), 8.74 (s, 4H); 13C NMR (50 MHz, CDCl3) δ 40.2, 
46.7, 53.6, 55.9, 60.7, 104.7, 126.5, 126.6, 129.7, 130.8, 135.8, 136.6, 150.9, 153.0, 
162.9; mp (di-paratoluensulfonates salt) 199-201°C; MS (ESI+) m/z = 735 (M +Na)+. 
Anal.(C52H56N4O16S2 · 2H2O), C, H, N 
2,7-Bis-[3-(3,4,5-trimethoxy-benzylamino)-propyl]-benzo[lmn][3,8] 
phenanthroline-1,3,6,8-tetraone (22): yellow oil; 85% yield; 1H NMR (free base, 
200 MHz, CDCl3) δ 1.99-2.06 (m, 4H + 2H exchangeable with D2O), 2.78 (t, 4H, J = 
6.8), 3.77 (s, 4H), 3.82 (s, 6H), 3.87 (12H), 4.32 (t, 4H, J = 6.9), 6.59 (s, 4H), 8.74 (s, 
4H); 13C NMR (50 MHz, CDCl3) δ 27.6, 38.4, 45.9, 49.7, 53.5, 55.6, 60.3, 104.5, 
125.9, 126.0, 130.3, 135.2, 136.2, 150.6, 152.6, 162.3; mp (di-paratoluensulfonates 
salt) 199-201°C; MS (ESI+) m/z = 741 (M +H)+. Anal.(C54H60N4O16S2 · 2H2O), C, H, 
N 
General Procedure for the Synthesis of 23-42: 
A mixture of the appropriate diamine and the appropriate aldehyde (in a 1:5 molar 
ratio) in toluene was refluxed in a Dean-Stark apparatus for 5 h. Following solvent 
removal, the residue was taken up in EtOH, NaBH4 (1:2.5 molar ratio) was added at 0 
°C, and the stirring was continued at room temperature for 4 h. The solvent was then 
removed and the residue was dissolved in dichloromethane and washed with brine. 
Removal of the dried solvent gave a residue that was purified by flash 
chromatography using as eluent a mixture of dichloromethane/methanol/acqueous 
33% ammonia (9:1:0.1), providing the desired products 23-42. 
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N1-(3-Methoxy-benzyl)-ethane-1,2-diamine (23): yellow oil; 22% yield; 1H NMR 
(free base, 400 MHz, CDCl3) δ 1.74 (brs, 3H exchangeable with D2O), 2.69 (t, 2H, J 
= 6), 2.81 (t, 2H, J = 5.6), 3.77 (s, 2H), 3.80 (s, 3H), 6.77-6.80 (m, 1H), 6.88-6.90 (m, 
2H), 7.21-7.26 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 41.3, 51.3, 53.5, 54.9, 112.1, 
113.4, 120.2, 129.1, 141.8, 159.5. 
N1-(3-Methoxy-benzyl)-propane-1,3-diamine (24): yellow oil; 60% yield; 1H NMR 
(free base, 400 MHz, CDCl3) δ 1.42 (brs, 3H exchangeable with D2O); 1.61-1.75 (m, 
2H), 2.68-2.84 (m, 4H), 3.79 (s, 2H), 3.83 (s, 3H), 6.78-6.83 (m, 1H), 6.90-6.93 (m, 
2H), 7.22-7.30 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 33.6, 40.5, 47.2, 54.0, 55.0, 
113.4, 120.3, 129.3, 142.2, 151.1, 159.7. 
N1-(4-Methoxy-benzyl)-ethane-1,2-diamine (25): yellow oil; 21% yield; 1H NMR 
(free base, 200 MHz, CDCl3) δ 1.53 (brs, 3H exchangeable with D2O), 2.68-2.74 (m, 
2H), 2.82-2.88 (m, 2H), 3.77 (s, 2H), 3.82 (s, 3H), 6.86-6.91 (m, 2H), 7.26-7.30 (m, 
2H); 13C NMR (50 MHz, CDCl3) δ 41.7, 51.8, 53.3, 55.3, 113.8, 129.3, 132.7, 158.6. 
N1-(4-Methoxy-benzyl)-propane-1,3-diamine: yellow oil; 51% yield; 1H NMR (free 
base, 200 MHz, CDCl3) δ 1.64-1.71 (m, 2H); 1.74 (brs, 3H exchangeable with D2O), 
2.67-2.82 (m, 4H), 3.74 (s, 2H), 3.81 (s, 3H), 6.85-6.90 (m, 2H), 7.23-7.27 (m, 2H); 
13C NMR (50 MHz, CDCl3) δ 33.2, 40.3, 46.9, 53.3, 55.0, 113.6,129.2, 132.3,158.5. 
N1-Benzyl-ethane-1,2-diamine (27): yellow oil; 22% yield; 1H NMR (free base, 200 
MHz, CDCl3) δ 1.70 (brs, 3H exchangeable with D2O), 2.69-2.74 (m, 2H), 2.81-2.86 
(m, 2H), 3.82 (s, 2H), 7.30-7.36 (m, 4H); 13C NMR (50 MHz, CDCl3) δ 41.5, 51.6, 
53.8, 127.0, 128.2, 128.4, 140.3. 
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N1-Benzyl-propane-1,3-diamine (28): yellow oil; 30% yield; 1H NMR (free base, 
200 MHz, CDCl3) δ 1.55-1.63 (m, 2H + 3H exchangeable with D2O), 2.65-2.73 (m, 
2H), 2.84-2.89 (m, 2H), 3.9 (s, 2H), 7.28-7.36 (m, 4H). 
N1-(2-Chloro-benzyl)-ethane-1,2-diamine (29): yellow oil; 25% yield; 1H NMR 
(free base, 200 MHz, CDCl3) δ 1.64 (brs, 3H exchangeable with D2O), 2.80 (t, 2H, J 
= 5.4), 2.91 (t, 2H, J = 5.2), 3.99 (s, 2H), 7.30-7.48 (m, 4 H); 13C NMR (50 MHz, 
CDCl3) δ 41.8, 51.4, 52.0, 127.1, 128.5, 129.7, 130.4, 138.0, 151.1. 
N1-(2-Chloro-benzyl)-propane-1,3-diamine (30): yellow oil; 35% yield; 1H NMR 
(free base, 200 MHz, CDCl3) δ 1.32-144 (m, 2H + 3H exchangeable with D2O), 2.36-
2.51 (m, 4H), 3.57 (s, 2H), 6.87-6.94 (m, 2H), 7.02-7.13 (m, 2H); 13C NMR (50 MHz, 
CDCl3) δ 33.3, 40.3, 47.0, 51.1, 126.6, 128.0, 129.2, 129.8,133.4, 137.7. 
N1-(2-Fluoro-benzyl)-ethane-1,2-diamine (31): yellow oil; 29% yield; 1H NMR 
(free base, 400 MHz, CDCl3) δ 1.45 (brs, 3H exchangeable with D2O), 2.68 (t, 2H, J 
= 6), 2.81 (t, 2H, J = 6), 3.85 (s, 2H), 7.00-7.05 (m, 1H), 7.08-7.12 (m, 1H), 7.20-7.26 
(m, 1H), 7.32-7.36 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 41.4, 46.8, 51.4, 115.1 
(J(C,F) = 86.8), 123.8 (J(C,F) = 16), 127.1 (J(C,F) = 58), 128.4 (J(C,F) = 32.4), 130.1 
(J(C,F) = 19.2), 162.15. 
N1-(2-Fluoro-benzyl)-propane-1,3-diamine (32): yellow oil; 55% yield; 1H NMR 
(free base, 400 MHz, CDCl3) δ 1.63-1.70 (m, 2H), 2.09 (brs, 3H exchangeable with 
D2O), 2.70 (t, 2H, J = 6.4), 2.80 (t, 2H, J = 6.8), 3.83 (s, 2H), 6.99-7.04 (m, 1H), 7.07-
7.11 (m, 1H), 7.19-7.26 (m, 1H), 7.29-7.34 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 
32.9, 40.5, 47.3, 47.4, 115.3 (J(C,F) = 86.8), 124.2 (J(C,F) = 12.8), 127.2 (J(C,F) = 
61.2), 128.8 (J(C,F) = 32.4), 130.5 (J(C,F) = 19.6), 160.1. 
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N1-(2-Nitro-benzyl)-ethane-1,2-diamine (33): yellow oil; 59% yield; 1H NMR (free 
base, 400 MHz, CDCl3) δ 1.71 (brs, 3H exchangeable with D2O), 2.71 (t, 2H, J = 5.2), 
2.83 (t, 2H, J = 5.8), 4.06 (s, 2H), 7.39-7.46 (m, 1H), 7.54-7.62 (m, 2H), 7.92-7.96 
(m, 1H); 13C NMR (100 MHz, CDCl3) δ 41.8, 50.7, 52.0, 124.8, 128.0, 131.2, 133.1, 
135.7, 147.8. 
N1-(2-Nitro-benzyl)-propane-1,3-diamine (34): yellow oil; 35% yield; 1H NMR 
(free base, 400 MHz, CDCl3) δ 1.55-1.60 (m, 2H), 1.84 (brs, 3H exchangeable with 
D2O), 2.59-2.74 (m, 4H), 3.94 (s, 2H), 7.28-7.36 (m, 1H), 7.49-7.52 (m, 2H), 7.81-
7.85 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 33.2, 40.4, 47.5, 50.9, 124.7, 127.9, 
131.2, 133.1, 135.7, 149.2. 
N1-(2-Trifluoromethyl-benzyl)-ethane-1,2-diamine (35): yellow oil; 67% yield; 1H 
NMR (free base, 400 MHz, CDCl3) δ 1.77 (brs, 3H exchangeable with D2O), 2.73 (t, 
2H, J = 6.2), 2.81 (t, 2H, J = 6.4), 3.96 (s, 2H), 7.28-7.65 (m, 4H); 13C NMR (400 
MHz, CDCl3) δ 41.4, 49.7, 51.7, 125.7, 126.8, 127.3, 127.8, 128.4, 130.2, 131.8. 
N1-(2-Trifluoromethyl-benzyl)-propane-1,3-diamine (36): yellow oil; 47% yield; 
1H NMR (free base, 200 MHz, CDCl3) δ 1.54 (brs, 3H exchangeable with D2O), 1.63-
1.76 (m, 2H), 2.72-2.85 (m, 4H), 3.97 (s, 2H), 7.29-7.67 (m, 4H); 13C NMR (100 
MHz, CDCl3) δ 31.3, 39.9, 47.4, 49.8, 125.7, 125.8, 126.9, 130.2, 131.9, 138.7. 
N1-(2-Methyl-benzyl)-ethane-1,2-diamine (37): yellow oil; 23% yield; 1H NMR 
(free base, 400 MHz, CDCl3) δ 1.57 (brs, 3H exchangeable with D2O), 2.72 (s, 3H), 
2.72-2.75 (m, 2H), 2.81-2.84 (m, 2H), 3.77 (s, 2H), 7.14-7.17 (m, 3H), 7.26-7.30 (m, 
1H); 13C NMR (100 MHz, CDCl3) δ 18.6 41.2, 51.1 51.7 125.5 126.5, 127.9 129.8, 
135.8, 137.9. 
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N1-(2-Methyl-benzyl)-propane-1,3-diamine (38): yellow oil; 42% yield; 1H NMR 
(free base, 200 MHz, CDCl3) δ 1.58-1.64 (m 2H), 2.01 (brs, 3H exchangeable with 
D2O), 2.29 (s, 3H), 2.64-2.75 (m, 4H), 3.69 (s, 2H), 7.09-7.14 (m, 3H), 7.21-7.24 (m, 
1H);13C NMR (100 MHz, CDCl3) δ 17.6, 31.8, 38.9, 46.4, 50.4, 124.5, 125.5, 126.9, 
128.8, 134.8, 137.2.  
N1-(2,3,4-Trimethoxy-benzyl)-ethane-1,2-diamine (39): yellow oil; 88% yield; 1H 
NMR (free base, 200 MHz, CDCl3) δ 2.1 (brs, 3H exchangeable with D2O), 2.66-2.75 
(m, 2H), 2.84 (t, 2H, J = 5.3), 3.74 (s, 2H), 3.85-3.92 (m, 9H), 6.61-6.65 (d, 1H, J = 
8.4), 6.94-6.98 (d, 1H, J = 8.4). 
N1-(2,3,4-Trimethoxy-benzyl)-propane-1,3-diamine (40): yellow oil; 51% yield; 1H 
NMR (free base, 200 MHz, CDCl3) δ 1.61-1.71 (m, 2H), 2.09 (brs, 3H exchangeable 
with D2O), 2.64 (t, 2H, J = 7.0), 2.75 (t, 2H, J = 6.6), 3.71 (s, 2H), 3.83-3.91 (m, 9H), 
6.59-6.63 (d, 1H, J = 8.4), 6.9-6.94 (d, 1H, J = 8.8). 
N1-(3,4,5-Trimethoxy-benzyl)-ethane-1,2-diamine (41): yellow oil; 82% yield; 1H 
NMR (free base, 200 MHz, CDCl3) δ 2.3 (brs, 3H exchangeable with D2O), 2.68 (t, 
2H, J = 5.4), 2.78 (t, 2H, J = 5.2), 3.67-3.80 (m, 11H), 6.52 (s, 2H); 13C NMR (50 
MHz, CDCl3) δ 40.8, 50.9, 53.5, 55.5, 60.2, 104.4, 135.6, 136.2, 152.6. 
N1-(3,4,5-Trimethoxy-benzyl)-propane-1,3-diamine (42): yellow oil; 91% yield; 1H 
NMR (free base, 200 MHz, CDCl3) δ 1.64(brs, 3H exchangeable with D2O), 1.2-1.76 
(m, 2H), 2.69 (t, 2H, J = 6.6), 2.81 (t, 2H, J = 7.0), 3.64 (s, 3H), 3.70 (s, 2H), 3.79 (s, 
3H), 3.83 (s, 3H), 6.55 (s, 2H); 13C NMR (50 MHz, CDCl3) δ 31.0, 39.4, 46.4, 53.5, 
55.7, 60.3, 104.7, 135.2, 136.3, 152.7. 
(B) Biology. Growth-Inhibiting Activity. The NCI screening is a two-stage 
process,19 beginning with the evaluation of all compounds against the 60 cell lines at a 
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single concentration of 10-5 M. Compounds exhibiting significant growth inhibition 
were evaluated against the 60-cell panel at five concentration levels by the NCI 
according to standard procedures (http://dtp.nci.nih.gov/branches/btb/ivclsp.html). In 
both cases the exposure time was 48 h. 
Indirect immunofluorescence of cellular microtubules and Tubulin assembly 
inhibition assay.  
Human A549 non small lung carcinoma cells were cultured in RPMI 1640 
supplemented with 10% FCS, glutamine, and antibiotics as previously described.41 
Indirect immunofluorescence was performed in A549 cells that had been cultured 
overnight in 12 mm round coverslips and incubated a further 24 hours in the absence 
(drug vehicle DMSO) or in the presence of different ligand concentrations. Attached 
cells were permeabilized with Triton X100 and fixed with 3.7 % formaldehyde. 
Microtubules were specifically stained with DM1A α-tubulin monoclonal antibodies 
and DNA with Hoechst 33342 as previously described.42 The preparations were 
examined using a Zeiss axioplan epifluorescence microscope and the images were 
recorded in a Hamamatsu 4742-95 cooled CCD camera. 
The effect of the compounds in the assembly of purified tubulin was determined by 
incubating 25 M purified tubulin at 37 ºC for 30 minutes in GAB (glycerol 
assembling buffer, 3.4 M glycerol, 10 mM sodium phospate, 1 mM EGTA, 1 mM 
GTP at pH 6.5) in the presence of 30 M test compound, docetaxel, or podofilotoxin  
or 2 L DMSO (vehicle). The samples were processed and the critical concentration 
for tubulin assembly43 in the presence of the ligands calculated as described.44 
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Cell death assays. Cell culture and treatment: HeLa cells were cultured in HAM’S F-
12 / MEM containing 10% fetal bovine serum, 5% glutamine, 1% non-essential amino 
acids  and antibiotic solution. All tested compounds were dissolved in 
dimethylsulphoxide, diluted to at 1000x solution and added to cell cultures. Control 
cells received the corresponding volume of the vehicle. Cell viability was determined 
by trypan blue exclusion by counting living cells and stained dead cells with a Burker 
hemocytometer. Samples were done in triplicate, and at least 10 fields were counted 
for each sample. At the end of the incubation, once the number of living cells in 
samples were measured, cell survival was calculated as the percentage of living viable 
cells in treated samples in respect to the number of viable cells in control samples. 
The IC50 value is the concentration of toxic compound required to reduce cell survival 
to 50%.  
The assays used to detect  apoptosis were: caspase activation and nuclear 
morphology. The activity of Caspase protease enzymes was measured by the cleavage 
of the fluorogenic peptide substrate AcDEVD-AMC. At the indicated time points, 
cells were washed in phosphate-buffered saline, harvested in 0.4 ml of lysis buffer, 
and subjected to two cycles of freeze-thawing. The lysates were centrifuged for 10v 
min. at 28,000×g at 4°C and the supernatant was then used to assay in duplicate 
enzyme activity. Extract (10 μl) was incubated for 15 min at 37°C in a final volume of 
30 μl to determine caspase activity.  
The effect of treatments on nuclear morphology was determined by the visualization 
of 4',6-diamidino-2-phenylindole (DAPI)-stained nuclei. At the indicated time point, 
cells grown in triplicate on glass coverslips were washed twice with cold PBS, fixed 
in ice-cold methanol/acetic acid (1:1, v/v) for 15 min., rinsed with PBS, and then 
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stained with 0.1 mg/ml of DAPI. After staining, cells were mounted on standard glass 
slides and observed with a IX50 Olympus inverted microscope (Olympus, Tokyo, 
Japan). Apoptotic cells were identified by nuclear features characteristic of apoptosis 
(nuclear shrinkage and/or fragmentation, chromatin condensation).  
Western blotting: Cells were collected in 5 mM dithiothreitol, 2 mM EDTA, 0.1% 
CHAPS, 0.1% Triton X-100, and protease inhibitors in 20 mM HEPES pH 7.5 and 
subjected to two cycles of freeze-thawing. The homogenate was then centrifuged at 
15,000 × g for 15 min and the supernatant, diluted in loading buffer (2% SDS, 5% 
glycerol, 0.002% bromophenol blue, 4% β-mercaptoethanol in 0.25 M Tris–HCl, pH 
6.8), and then denatured by boiling for 4 min. Aliquots corresponding to 80 μg protein 
were analyzed by SDS-PAGE. Proteins were transferred onto a nitrocellulose 
membrane and probed with the specific primary antibody. After further washing, the 
membrane was then incubated for 1h with peroxidase-conjugated goat anti-rabbit IgG 
(Santa Cruz). Immunoreactive bands were visualized by chemioluminescence with the 
ECL reagent (Amersham).  Antibodies against total and phosphorylated ERK1/2 were 
from Cell Signaling. Anti actin was obtained from Santa Cruz. Actin was used as 
internal control. 
DNA binding assays.  
The binding to DNA was determined by a fluorometric ethidium displacement test at 
pH 8.24, 25 The assay mixture contained 2 µg of ethidium bromide and  0.5 µg of calf 
thymus DNA in a final volume of 2 ml. Fluorescence (excitation at 525 nm; emission 
at 600 nm) was determined in triplicate following addition of aliquots of a 100x 
solution  of polyamine compounds. The EC50 values are defined as the drug 
concentration which reduces the fluorescence of the DNA-bound ethidium by 50%. 
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Fluorescence melting assay. Fluorescence melting curves were determined in a 
Roche LightCycler (λecc 470 nm, λemm 520 nm) in LiP buffer (10 mM LiOH, 50 
mM KCl, pH 7.4 with H3PO4). increasing ligands concentrations were added to 0.25 
μM final concentration of a labelled human telomeric sequence (5’-Dabcyl-
AGGGTTAGGGTTAGGGTTAGGGT-FAM 3’, Eurogentec, Belgium). Before scan 
acquisition the reaction mixture was first denatured and annealed. Then, samples were 
maintained at 30° for 5 min before being slowly heated to 95 °C (1°C/ min) and 
annealed at a rate of 1°C/min. When double stranded DNA was used, dsUP (5’-FAM- 
ACTATTCCCGGGTAATGA) and dsDOWN (TCATTACCCGGGAATAGT- 
Dabcyl 3’) were mixed at equimolar concentrations, heated to 95°C for 5 min, and 
then cooled to room temperature overnight before use. Recordings were taken during 
both the annealing and melting steps.  
Tm values were determined from the first derivatives of the melting profiles using the 
Roche LightCycler software. Each curve was repeated at least three times and errors 
were ± 0.4°C. 
Circular dichroism measurements. Circular dichroism spectra from 230 to 450 nm 
were recorded using 10 mm path length cells on a Jasco J 810 spectropolarimeter 
equipped with a NESLAB temperature controller and interfaced to a PC 100 in 10 
mM Tris-HCl, 50 mM KCl pH 7.4. Experiments were performed by ligands to a 
solution of 4 M Tel 22(5’-AGGGTTAGGGTTAGGGTTAGGG-3’, Eurogentec, 
Belgium ) or 45 M ctDNA (Sigma). Before data acquisition, Tel22 solutions were 
heated at 95°C for 5 min and left to cool at room temperature o.n.. The reported 
spectrum of each sample represents the average of 3 scans recorded with 1-nm step 
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resolution. Observed ellipticities were converted to mean residue ellipticity [] = deg 
x cm2 x dmol-1 (Mol. Ellip.). 
UV-VIS spectroscopic titrations. Spectrophotometric titrations were performed in 
10 mM Tris-, 20 mM KCl, pH 7.5with a Perkin-Elmer Lambda 12 apparatus. Binding 
was followed by addition of increasing amounts of DNA to a freshly prepared drug 
solution. For each drug/DNA ratio the fraction of bound ligand was calculated ( = (-
o)/( ∞- 0), where o and  are the extinction coefficient of the free and DNA-bound 
ligand, respectively). To avoid large systematic inaccuracies due to experimental 
errors, the range of bound drug fractions utilized for calculations was 0.15-0.85. For 
titrations with ctDNA, data were evaluated according to the equation of McGhee and 
Von Hippel for non-coopative ligand-lattice interactions.45 G-quadruoplex isotherms 
were analyzed according to a single set of identical sites.  
Taq Polymerase Assay. Taq polymerase reaction in the presence/absence of ligands 
and their metal complexes were performed using pBR322 (2.5 ng) as a DNA template 
and appropriate primer sequences Tup and Tdown (0.5 M) to amplify the 906-1064 
sequence of plasmid by PCR. The reaction was carried out in an Eppendorf 
thermocycler performing 25 cycles of: 30 s at 94°C, 30 s at 65 °C and 30 s at 72 °C. 
The reaction products were resolved on a 2% agarose gel in 1X TBE (89 mM Tris 
base, 89 mM boric acid, 2 mM Na2EDTA) and stained by ethidium bromide. 
Telomerase Activity Assay. 8 x104 HeLa cells in exponential phase of growth were 
seeded In a 6-wells plate. After 24h they were treated with increasing concentration of 
drug and incubated for further 24 h. Then, cells were pelleted and lysed for 30 min on 
ice using 100 µl of 0.5% CHAPS, 1 mM EGTA, 25% 2-mercaptoethanol, 1.74% 
PMSF and 10% w/v glycerol. The lysate was centrifuged at 13000 rpm for 30 min at 4 
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°C and the supernatant used as telomerase source. Telomerase activity was assayed 
using TRAPeze telomerase detection kit (Chemicon International). The reaction 
products were loaded onto a 10% polyacrylamide gel (19:1) in TBE 0.5X. Gels were 
stained with SbrGreen I. 
In vitro screening in human tumor cell lines. Drug stock solutions (1 x 10-2 M) 
were prepared in cell culture DMSO. These were initially diluted in phosphate buffer 
saline (1 x 10-3 M) and finally in complete growth medium (1 x 10-4 M). Several µL 
were taken and put into cell culture plates to obtain different drug concentrations 
(highest final DMSO concentration was 0,05%). All controls contained the highest 
DMSO concentration used in the treated samples. 
Cells were plated in 96-well tissue culture plates, allowed to attach 24 hours, and then 
left untreated or treated with growth medium containing 0.25, 0.50, 0.75, 1.0, 1.25, 
1.5, 1.75, 2.0 µM 2,14,16, or 18. Briefly, fifteen μL of 5 mg/mL  3-(4,5-
diphenyltetrazolium) bromide (MTT) in PBS were then added to each well  and cells 
were incubated for 4 h at 37°C. Formazan crystals were made soluble with DMSO (all 
reagents were from Sigma-Aldrich (St. Louis, MO, USA). Optical densities were 
determined at 570 nm using a Dynatech MR5000 plate reader. Viability was 
expressed as a percentage of control by dividing the absorbance of each treated well 
by the average of the untreated controls. Cytotoxicity was determined by plotting cell 
viability versus drug concentrations. Results, derived from three different 
experiments, are expressed as mean percentage from quadruplicate wells as compared 
to that of control cells. The IC50 of the tested compounds were estimated graphically 
from the dose-response curves after 48 h of drug exposure. 
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Analysis of DNA synthesis by pulse labeling with bromodeoxyuridine. 
Exponentially growing neuroblastoma cells HTLA-230 were treated for 24 hours or 
48 hours with 1.50 µM of 20, pulse labelled with 10µM bromodeoxyuridine (BrdU; 
Sigma) for 1 hour, harvested by scraping, washed twice with 1 % bovine serum 
albumin (BSA) in PBS, and fixed with 70 % ice-cold ethanol for 30 minutes at 4°C. 
The cells were incubated for 30 minutes at room temperature in 2N HCl/0.5 % Triton 
X-100 to denature the DNA and to produce single-stranded molecules, then washed 
with 0.1 M Na2B407 (pH 8.5) to neutralize the acid, and resuspended in 0.5 % Tween 
20/1 % BSA/PBS. BrdU uptake was detected by staining the cells with 20µL 
fluorescein isothiocynate (FITC)-conjugated mouse monoclonal anti-BrdU antibody 
(Becton Dickinson, Milan, Italy) at final concentration of 5 µg/mL for 30 minutes at 
room temperature. The cells were washed and resuspended in PBS containing 5 
µg/mL propidium iodide (PI). Bivariate distributions of BrdU amounts (fluorescein 
isothiocynate, y-axis) versus DNA content (propidium iodide, x-axis) were assessed 
by flow cytometry using FACScan device (Beckton Dickinson) equipped with a 
xenon lamp and a filter set for excitation at 488 nm; FITC and PI fluorescence 
intensities were recorded through 520- to 530-nm and 575-nm filters, respectively. At 
least 100 000 cells were analyzed to produce each final densitometric plot. The gates 
represent the different phases of the cell cycle (R1 = sub-G1 phase, R2 = G1 phase, R3 
= S phase, R4 = G2/M phase). 
Annexin V-FITC/PI stained fluorescence-activated cell sorter (FACS). To assess 
the effect of 20 on apoptosis, OVCAR 3.0 cells were stained with Annexin V-FITC/PI 
according to the manufacturer’s instructions (Immunostep, S.L.; Salamanca, Spain). 
Briefly, adherent cells were plated at a concentration of 90 x 105 cells/well, 6-well 
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plate and after 24 h treated with 20 at 1.5, 2.0 or 2.5 µM. After  48 h or 72 h 
incubation cells were detached with scraper and washed twice with cold PBS and then 
suspended in 1x Binding Buffer at a concentration of 1 x 106 cells/mL. Hundred 
microliters of the suspension were transferred to a 5 mL tube and  5 µL of Annexin V-
FITC and 5 µL of PI  were added. The samples were gently vortexed and incubated 
for 15 min at 25°C in the dark. Finally, 400 µL of 1x Binding Buffer were added to 
each tube and the samples were analyzed by flow cytometry within 1 h at two 
wavelengths 515 and 639 nm. The used flow cytometer was a FACScan (Becton 
Dickinson) and the analysis was performed with Cell Quest software. Vehicle 
(DMSO) treated unstained  and stained cells were used as controls. 
Statistics 
For the experiments involving in vitro drug treatment mean values and standard 
deviation for untreated and treated groups at different times were calculated. In 
addition, statistical significance of differences between untreated and treated groups at 
different times was determined by Mann-Whitney test., two tailed, with 
95%confidence intervals using GraphPad Prism 3.0 software (GraphPad Software, 
Inc.). 
 
Acknowledgment. This research was supported by a grant from MIUR, Rome 
(PRIN), University of Bologna (RFO) and Polo Scientifico-Didattico di Rimini (to 
V.T.). We thank the National Cancer Institute (Bethesda, MD) for the anticancer 
assays. MICINN (Spanish Government) is acknowledged for grant BIO2010-16351 
(to J.F.D.). Lizzia Raffaghello is a recipient of MFAG Grant. Giovanna Bianchi is a 




Supporting Information Available. Experimental details for chemistry, biology, 
characterization and elemental analyses of target compounds, and experimental details 
and characterization of intermediate compounds. This material is available free of 
charge via the Internet at http://pubs.acs.org. 
 51 
References 
1. Takenaka, S.; Takagi, M. Threading Intercalators as a New DNA Structural 
Probe. Bulletin of the Chemical Society of Japan 1999, 72, 327-337. 
2. Brana, M. F.; Cacho, M.; Gradillas, A.; de Pascual-Teresa, B.; Ramos, A. 
Intercalators as anticancer drugs. Curr Pharm Des 2001, 7, 1745-80. 
3. Martinez, R.; Chacon-Garcia, L. The search of DNA-intercalators as 
antitumoral drugs: what it worked and what did not work. Curr. Med. Chem. 2005, 
12, 127-51. 
4. Tumir, L. M.; Piantanida, I. Recognition of single stranded and double 
stranded DNA/RNA sequences in aqueous medium by small bis-aromatic derivatives. 
Mini Rev Med Chem 2010, 10, 299-308. 
5. Strekowski, L.; Wilson, B. Noncovalent interactions with DNA: an overview. 
Mutat Res 2007, 623, 3-13. 
6. Nojima, T.; Ohtsuka, K.; Nagamatsu, T.; Takenaka, S. Bis-naphthalene 
diimide exhibiting an effective bis-threading intercalating ability. Nucleic Acids Res 
Suppl 2003, 123-4. 
7. Gianolio, D. A.; McLaughlin, L. W. Tethered naphthalene diimide 
intercalators enhance DNA triplex stability. Bioorg Med Chem 2001, 9, 2329-34. 
8. Balasubramanian, S.; Neidle, S. G-quadruplex nucleic acids as therapeutic 
targets. Curr Opin Chem Biol 2009, 13, 345-53. 
9. Di Antonio, M.; Doria, F.; Richter, S. N.; Bertipaglia, C.; Mella, M.; Sissi, C.; 
Palumbo, M.; Freccero, M. Quinone methides tethered to naphthalene diimides as 
selective G-quadruplex alkylating agents. J Am Chem Soc 2009, 131, 13132-41. 
10. Gunaratnam, M.; Swank, S.; Haider, S. M.; Galesa, K.; Reszka, A. P.; Beltran, 
M.; Cuenca, F.; Fletcher, J. A.; Neidle, S. Targeting human gastrointestinal stromal 
tumor cells with a quadruplex-binding small molecule. J Med Chem 2009, 52, 3774-
83. 
11. Liu, Z. R.; Hecker, K. H.; Rill, R. L. Selective DNA binding of (N-
alkylamine)-substituted naphthalene imides and diimides to G+C-rich DNA. J. 
Biomol. Struct. Dyn. 1996, 14, 331-9. 
12. Tumiatti, V.; Milelli, A.; Minarini, A.; Micco, M.; Gasperi Campani, A.; 
Roncuzzi, L.; Baiocchi, D.; Marinello, J.; Capranico, G.; Zini, M.; Stefanelli, C.; 
Melchiorre, C. Design, synthesis, and biological evaluation of substituted naphthalene 
imides and diimides as anticancer agent. J Med Chem 2009, 52, 7873-7. 
13. Schneider, H. J. Ligand binding to nucleic acids and proteins: Does selectivity 
increase with strength? Eur J Med Chem 2008, 43, 2307-15. 
14. Tumiatti, V.; Rosini, M.; Bartolini, M.; Cavalli, A.; Marucci, G.; Andrisano, 
V.; Angeli, P.; Banzi, R.; Minarini, A.; Recanatini, M.; Melchiorre, C. Structure-
activity relationships of acetylcholinesterase noncovalent inhibitors based on a 
polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen 
atoms of caproctamine. J Med Chem 2003, 46, 954-66. 
15. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; 
Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat 
neurodegenerative diseases. J Med Chem 2008, 51, 347-72. 
16. Petrelli, A.; Valabrega, G. Multitarget drugs: the present and the future of 
cancer therapy. Expert Opinion on Pharmacotherapy 2009, 10, 589-600. 
 52 
17. Hagmann, W. K. The many roles for fluorine in medicinal chemistry. J Med 
Chem 2008, 51, 4359-69. 
18. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: 
cancer drug discovery and development program. Semin Oncol 1992, 19, 622-38. 
19. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; 
Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; et al. Feasibility of a high-flux 
anticancer drug screen using a diverse panel of cultured human tumor cell lines. J 
Natl Cancer Inst 1991, 83, 757-66. 
20. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J., 
Jr.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; 
Buolamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. 
A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; 
Paull, K. D. An information-intensive approach to the molecular pharmacology of 
cancer. Science 1997, 275, 343-9. 
21. Lavrik, I. N.; Golks, A.; Krammer, P. H. Caspases: pharmacological 
manipulation of cell death. J Clin Invest 2005, 115, 2665-72. 
22. Robertson, J. D.; Orrenius, S.; Zhivotovsky, B. Review: nuclear events in 
apoptosis. J Struct Biol 2000, 129, 346-58. 
23. Balmanno, K.; Cook, S. J. Tumour cell survival signalling by the ERK1/2 
pathway. Cell Death Differ 2009, 16, 368-77. 
24. Morgan, A. R.; Lee, J. S.; Pulleyblank, D. E.; Murray, N. L.; Evans, D. H. 
Review: ethidium fluorescence assays. Part 1. Physicochemical studies. Nucleic Acids 
Res 1979, 7, 547-69. 
25. McConnaughie, A. W.; Jenkins, T. C. Novel acridine-triazenes as prototype 
combilexins: synthesis, DNA binding, and biological activity. J Med Chem 1995, 38, 
3488-501. 
26. LigPrep, version 2.3. In Schroedinger LLC: New York, 2009. 
27. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; 
Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel - an Integrated 
Software System for Modeling Organic and Bioorganic Molecules Using Molecular 
Mechanics. Journal of Computational Chemistry 1990, 11, 440-467. 
28. Mcdonald, D. Q.; Still, W. C. Amber-Asterisk Torsional Parameters for the 
Peptide Backbone. Tetrahedron Letters 1992, 33, 7743-7746. 
29. Hasel, D.; Hendrickson, T. F.; Still, W. C. A rapid approximation to the 
solvent accessible surface areas of atoms. Tetrahedron Comput. Methodol. 1988, 1, 
103-116. 
30. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, 
H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res 2000, 
28, 235-42. 
31. Canals, A.; Purciolas, M.; Aymami, J.; Coll, M. The anticancer agent 
ellipticine unwinds DNA by intercalative binding in an orientation parallel to base 
pairs. Acta Crystallogr D Biol Crystallogr 2005, 61, 1009-12. 
32. Parkinson, G. N.; Cuenca, F.; Neidle, S. Topology conservation and loop 
flexibility in quadruplex-drug recognition: crystal structures of inter- and 
intramolecular telomeric DNA quadruplex-drug complexes. J Mol Biol 2008, 381, 
1145-56. 
 53 
33. Alcaro, S.; Ortuso, F.; Coleman, R. S. DNA cross-linking by azinomycin B: 
Monte Carlo simulations in the evaluation of sequence selectivity. J Med Chem 2002, 
45, 861-70. 
34. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, 
R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an 
empirical binding free energy function. Journal of Computational Chemistry 1998, 
19, 1639-1662. 
35. Alcaro, S.; Gasparrini, F.; Incani, O.; Caglioti, L.; Pierini, M.; Villani, C. 
"Quasi flexible" automatic docking processing for studying stereoselective 
recognition mechanisms, part 2: Prediction of Delta Delta G of complexation and H-
1-NMR NOE correlation. Journal of Computational Chemistry 2007, 28, 1119-1128. 
36. Alcaro, S.; Gasparrini, F.; Incani, O.; Mecucci, S.; Misiti, D.; Pierini, M.; 
Villani, C. A "quasi-flexible" automatic docking processing for studying 
stereoselective recognition mechanisms. Part I. Protocol validation. Journal of 
Computational Chemistry 2000, 21, 515-530. 
37. Alcaro, S.; Artese, A.; Iley, J. N.; Missailidis, S.; Ortuso, F.; Parrotta, L.; 
Pasceri, R.; Paduano, F.; Sissi, C.; Trapasso, F.; Vigorita, M. G. Rational Design, 
Synthesis, Biophysical and Antiproliferative Evaluation of Fluorenone Derivatives 
with DNA G-Quadruplex Binding Properties. Chemmedchem 2010, 5, 575-583. 
38. Alcaro, O.; Costa, G.; Distinto, S.; Moraca, F.; Ortuso, F.; Parrotta, L.; Artese, 
A. The polymorfism of DNA G-Quadruplex investigated by Docking Experiments 
with Telemestatin Enantiomers. Curr. Pharm. Des. 2011, accepted. 
39. Wolber, G.; Langer, T. LigandScout: 3-d pharmacophores derived from 
protein-bound Ligands and their use as virtual screening filters. Journal of Chemical 
Information and Modeling 2005, 45, 160-169. 
40. Alcaro, S.; Artese, A.; Iley, J. N.; Maccari, R.; Missailidis, S.; Ortuso, F.; 
Ottana, R.; Ragazzon, P.; Vigorita, M. G. Tetraplex DNA specific ligands based on 
the fluorenone-carboxamide scaffold. Bioorganic & Medicinal Chemistry Letters 
2007, 17, 2509-2514. 
41. Buey, R. M.; Calvo, E.; Barasoain, I.; Pineda, O.; Edler, M. C.; Matesanz, R.; 
Cerezo, G.; Vanderwal, C. D.; Day, B. W.; Sorensen, E. J.; Lopez, J. A.; Andreu, J. 
M.; Hamel, E.; Diaz, J. F. Cyclostreptin binds covalently to microtubule pores and 
lumenal taxoid binding sites. Nat Chem Biol 2007, 3, 117-25. 
42. de Ines, C.; Leynadier, D.; Barasoain, I.; Peyrot, V.; Garcia, P.; Briand, C.; 
Rener, G. A.; Temple, C., Jr. Inhibition of microtubules and cell cycle arrest by a new 
1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 
613863. Cancer Res 1994, 54, 75-84. 
43. Oosawa, F. A., S. Thermodynamics of the Polymerization of Proteins. London, 
1975. 
44. Buey, R. M.; Barasoain, I.; Jackson, E.; Meyer, A.; Giannakakou, P.; Paterson, 
I.; Mooberry, S.; Andreu, J. M.; Diaz, J. F. Microtubule interactions with chemically 
diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts 
cytotoxicity. Chem Biol 2005, 12, 1269-79. 
45. McGhee, J., von Hippel, P. . Theoretical aspects of DNA-protein interactions: 
co-operative and non co-operative binding of large ligands to a one-dimensional 








Table of Contents Graphic 
NN
O
O
O
O
n N
H
N
H
n
n = 2-3
R R
 
 
 
 
  
 
